You have found 141 entries after clicking the GO button or a search link in a hot topic. Starting with analyses of the most recently published documents, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the most recently added or updated entries or by the main topic addressed
If you have not found what you want you could:
Select from the full range of topics and search options available on our topic search page.
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo
How do different pathways for the treatment of problem opioid use compare under real-world conditions? For US patients with health insurance, opioid substitution therapy was associated with the greatest risk reduction. However, its protective effect may not be fully realised while federal and insurance plan restrictions continue to limit access to this treatment option.
Can a limited period of being prescribed opiate-type medications generate longer term reductions in the criminal behaviour of patients dependent on illegal opiates like heroin? And of the two main medications – buprenorphine and methadone – which performs best? It seems a key factor is how well they retain patients in treatment.
In the Canadian province of British Columbia there was a rapid rise in overdose deaths from 2015, leading to the declaration of a public health emergency in 2016. The response rested on three key interventions: take-home naloxone, opioid substitution therapy, and drug consumption rooms. The province’s highly detailed surveillance data offered an opportunity to estimate their collective and individual impacts on opioid overdose deaths.
In the new form of extended-release injections with effects lasting a month, the opioid medication buprenorphine was found to suppress illegal opioid use more effectively than a placebo, reinforcing its promise as a possible “game-changer” in opiate addiction treatment.
From the USA, a rare randomised trial found in favour of continuing methadone maintenance when patients entered prison rather than compulsory withdrawal. The potential benefits were most apparent in the near-100% continuation of protective treatment during the highly overdose-prone weeks after leaving prison.
Expanding access to medication is an important public health strategy for tackling opioid use disorder, concludes US government agency guidelines. While some people stop using opioids without medication, many benefit from access to methadone, naltrexone, and buprenorphine for varying lengths of time, including lifelong treatment.
In the new form of extended-release injections whose effects last up to a month, the opioid medication buprenorphine was found to suppress illegal opioid use more effectively than the standard daily regimen.
MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell B3: Practitioners; Medical treatment
Seminal and key research and reviews on the influence of the practitioner in the medical treatment of drug dependence. Investigates the how clinician-patient relationships might be affected by enforcing clinic rules and the potential importance of doctors forming a “whole person’ relationship with patients.
HOT TOPIC 2017 HTM file
Overdose deaths in the UK: crisis and response
One of our selection of hot topics – important issues which sometimes generate heated debate. Why did the fall in UK drug overdose deaths in 2009 to 2012 so decisively reverse in the following years? A life-threatening turn away from harm reduction, or simply an ageing population of heroin users?
Trials challenge the need for the widely accepted policy of making opioid-dependent patients take their methadone or other opioid substitutes at the clinic or pharmacy, but ‘no difference’ findings may be due to the limitations of the research.
Select search results pageNEXT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15